Cargando…

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial

BACKGROUND: Children are susceptible to severe influenza infections and facilitate community transmission. One potential strategy to improve vaccine immunogenicity in children against seasonal influenza involves a trivalent hemagglutinin DNA prime-trivalent inactivated influenza vaccine (IIV3) boost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houser, Katherine V., Yamshchikov, Galina V., Bellamy, Abbie R., May, Jeanine, Enama, Mary E., Sarwar, Uzma, Larkin, Brenda, Bailer, Robert T., Koup, Richard, Paskel, Myeisha, Subbarao, Kanta, Anderson, Edwin, Bernstein, David I., Creech, Buddy, Keyserling, Harry, Spearman, Paul, Wright, Peter F., Graham, Barney S., Ledgerwood, Julie E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214651/ https://www.ncbi.nlm.nih.gov/pubmed/30388160 http://dx.doi.org/10.1371/journal.pone.0206837

Ejemplares similares

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial
por: Ledgerwood, Julie E., et al.
Publicado: (2015)

Nonreplicating Influenza A Virus Vaccines Confer Broad Protection against Lethal Challenge
por: Baz, Mariana, et al.
Publicado: (2015)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
por: Crank, Michelle C., et al.
Publicado: (2015)

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2015)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses
por: Paules, Catharine I, et al.
Publicado: (2017)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
por: DeZure, Adam D., et al.
Publicado: (2017)

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013)

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?
por: Anderson, Evan J, et al.
Publicado: (2020)

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
por: Martin, Julie E., et al.
Publicado: (2008)

Vaccines for Pandemic Influenza
por: Luke, Catherine J., et al.
Publicado: (2006)

The success of SARS-CoV-2 vaccines and challenges ahead
por: Subbarao, Kanta
Publicado: (2021)

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults
por: Enama, ME, et al.
Publicado: (2009)

H5N1 Viruses and Vaccines
por: Subbarao, Kanta, et al.
Publicado: (2007)

Respiratory Virus Vaccines
por: Broadbent, Andrew J., et al.
Publicado: (2015)

The Role of Animal Models In Influenza Vaccine Research
por: Luke, Catherine J., et al.
Publicado: (2010)

The role of animal models in influenza vaccine research
por: Luke, Catherine J., et al.
Publicado: (2008)

Scientific barriers to developing vaccines against avian influenza viruses
por: Subbarao, Kanta, et al.
Publicado: (2007)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
por: Roy, Vicky, et al.
Publicado: (2023)

The soft palate is an important site of adaptation for transmissible influenza viruses
por: Lakdawala, Seema S., et al.
Publicado: (2015)

2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination
por: Anderson, Evan J, et al.
Publicado: (2018)

994. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells
por: Howard, Leigh, et al.
Publicado: (2018)

1113 Safety and Efficacy of a Cytomegalovirus Glycoprotein B (gB) Vaccine in Adolescent Girls
por: Bernstein, David I., et al.
Publicado: (2014)

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
por: Gaudinski, Martin R., et al.
Publicado: (2018)

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
por: Gaudinski, Martin R, et al.
Publicado: (2018)

H5N1 Vaccine-Specific B Cell Responses in Ferrets Primed with Live Attenuated Seasonal Influenza Vaccines
por: Cheng, Xing, et al.
Publicado: (2009)

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)
por: Creech, C Buddy, et al.
Publicado: (2019)

SARS Vaccine Protective in Mice
por: Stadler, Konrad, et al.
Publicado: (2005)

P15-30 LB. An evaluation of prescreen recruitment data: enrolling racial/ethnic minorities in Phase I HIV vaccine clinical trials
por: Johnson, D, et al.
Publicado: (2009)

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
por: Tapia, Milagritos D, et al.
Publicado: (2016)

Update on policy change proposal to end Institutional Biosafety Committee (IBC) review of rDNA vaccine clinical trials
por: Enama, ME, et al.
Publicado: (2012)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines
por: Sutton, Troy C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_saldaivljpcdaommvhor8rc1k6